Last Price
11.84
Today's Change
+0.44 (3.85%)
Day's Change
11.40 - 12.54
Trading Volume
632,045
Market Cap
623 Million
Shares Outstanding
52 Million
Avg Volume
558,792
Avg Price (50 Days)
13.85
Avg Price (200 Days)
11.22
PE Ratio
-5.46
EPS
-2.17
Earnings Announcement
05-Nov-2024
Previous Close
11.40
Open
11.40
Day's Range
11.4 - 12.54
Year Range
3.35 - 17.58
Trading Volume
632,045
1 Day Change
3.86%
5 Day Change
0.51%
1 Month Change
-13.64%
3 Month Change
-16.91%
6 Month Change
-7.28%
Ytd Change
102.05%
1 Year Change
202.04%
3 Year Change
-49.68%
5 Year Change
-42.13%
10 Year Change
-53.70%
Max Change
-53.70%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.